Wang S L, Huang J, Lai M D, Tsai J J
Department of Pharmacology, National Cheng Kung University, Medical College, Taiwan, Republic of China.
Pharmacogenetics. 1995 Feb;5(1):37-42. doi: 10.1097/00008571-199502000-00004.
Cytochrome P450 (CYP) 2C9 catalyses the metabolism of a wide range of drugs. Previous studies have shown the differences in the amino acid composition among CYP2C9 variants at Cys144/Arg, Tyr358/Cys, Leu359/Ile, and Gly417/Asp. PCR-endonuclease digestion methods have been developed to detect these four possible polymorphisms. The T416-->C mutation in exon 3 of CYP2C9 (Cys144-->Arg) creates an Ava II site. In the 135 subjects we tested, all leukocyte DNA samples showed a complete Ava II digestion indicating homozygous C416 (Arg144). A Tyr358-->Cys mutation will create a Nsi I site at codon 1057-1063 in exon 7. In 40 subjects tested, all samples showed negative results. DNA sequencing on a few samples showed Tyr358Ile359. A mismatched PCR primer pair was then designed to detect codon C1061-->A (Leu359-->Ile) mutation. In 115 subjects tested, 111 samples showed a complete Nsi I digestion (Ile359) and four samples showed heterozygous results. Another mismatched PCR primer pair was used to confirm the C1061 codon in heterozygous subjects. The four heterozygous subjects showed partial digestion with endonuclease Kpn I, which confirmed the heterozygous Ile/Leu at amino acid 359. The G1236-->A mutation in exon 8 of CYP2C9 (Gly417-->Asp) creates a Hph I site. In all 46 subjects, homozygous G1236 (Gly417) was found. Most Chinese subjects actually have Arg144 Tyr358 Ile359 Gly417 in CYP2C9 as previously reported human-2. Furthermore, we found an A-->T (+12 position in intron 2) mutation in our CYP2C9 sequencing process. The mutation creates a NIa III site.(ABSTRACT TRUNCATED AT 250 WORDS)
细胞色素P450(CYP)2C9催化多种药物的代谢。先前的研究表明,CYP2C9变体在半胱氨酸144/精氨酸、酪氨酸358/半胱氨酸、亮氨酸359/异亮氨酸和甘氨酸417/天冬氨酸处的氨基酸组成存在差异。已开发出聚合酶链反应-内切酶消化方法来检测这四种可能的多态性。CYP2C9第3外显子中的T416→C突变(半胱氨酸144→精氨酸)产生一个Ava II位点。在我们检测的135名受试者中,所有白细胞DNA样本均显示Ava II完全消化,表明为纯合子C416(精氨酸144)。酪氨酸358→半胱氨酸突变将在第7外显子的密码子1057 - 1063处产生一个Nsi I位点。在检测的40名受试者中,所有样本结果均为阴性。对少数样本进行的DNA测序显示为酪氨酸358异亮氨酸359。然后设计了一对错配的聚合酶链反应引物来检测密码子C1061→A(亮氨酸359→异亮氨酸)突变。在检测的115名受试者中,111个样本显示Nsi I完全消化(异亮氨酸359),4个样本显示杂合结果。使用另一对错配的聚合酶链反应引物来确认杂合受试者中的C1061密码子。这四名杂合受试者的样本经内切酶Kpn I消化后显示部分消化,证实了氨基酸359处为异亮氨酸/亮氨酸杂合。CYP2C9第8外显子中的G1236→A突变(甘氨酸417→天冬氨酸)产生一个Hph I位点。在所有46名受试者中,均发现为纯合子G1236(甘氨酸417)。如先前报道的人类-2一样,大多数中国受试者CYP2C9中实际上具有精氨酸144、酪氨酸358、异亮氨酸359、甘氨酸417。此外,我们在CYP2C9测序过程中发现了一个A→T(内含子2中的+12位置)突变。该突变产生一个NIa III位点。(摘要截短至250字)